He and colleagues developed a transient, non-gene-editing platform for off-the-shelf allogeneic TCR-T therapy. By conferring tacrolimus resistance characteristics to IL-2/4/7 expanded TCR-T cells that display reduced alloreactivity, He et al. provided a proof-of-concept for an allogeneic TCR-T therapy approach that addresses both manufacturability, and unwanted graft and host alloreactivity concerns.

CAR T cells engineered to secrete tumor-localized anti-EpCAM bispecific T cell engagers (BTCEs) overcome antigen escape and heterogeneity across multiple epithelial carcinomas in preclinical models, achieving complete tumor eradication where conventional single-target CAR T cell therapies often failed, supporting broad translational potential for solid tumor immunotherapy.